ArticleBMJ medicine2026

Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation.

Yan Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.